Source: http://www.google.es/patents/US8685994
Timestamp: 2018-01-19 16:06:10
Document Index: 21731915

Matched Legal Cases: ['Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 2000109552']

Patente US8685994 - Analgesic combination of oxycodone and celecoxib - Google Patentes
Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic...http://www.google.es/patents/US8685994?utm_source=gb-gplus-sharePatente US8685994 - Analgesic combination of oxycodone and celecoxib
Número de publicación US8685994 B2
También publicado como CA2303309A1, CA2303309C, CN1241567C, CN1278158A, DE69827821D1, DE69827821T2, DE69841590D1, EP1014886A1, EP1014886A4, EP1014886B1, EP1518555A1, EP1518555B1, US6552031, US8143267, US8168629, US8188107, US8193209, US20020099049, US20020099064, US20020107259, US20020132825, US20020143028, US20020151559, US20020156091, US20070191412, US20080050427, US20120252794, WO1999013799A1
Número de publicación 11698394, 698394, US 8685994 B2, US 8685994B2, US-B2-8685994, US8685994 B2, US8685994B2
Inventores Ronald M. Burch, Paul D. Goldenheim, Richard S. Sackler
Cesionario original Purdue Pharma, L.P.
Citas de patentes (65), Otras citas (217), Citada por (3), Clasificaciones (26), Eventos legales (1)
Analgesic combination of oxycodone and celecoxib
US 8685994 B2
US3800041 2 Mar 1971 26 Mar 1974 Lilly Co Eli Analgesic compositions and methods
US4322427 16 Abr 1981 30 Mar 1982 Bristol-Myers Company Analgetic compositions and methods of use
US4338324 17 Mar 1981 6 Jul 1982 Mcneilab, Inc. Analgesic potentiation
US4567183 12 Dic 1983 28 Ene 1986 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US5190947 16 Ago 1991 2 Mar 1993 Ciba-Geigy Corporation Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof
US5240694 19 Nov 1991 31 Ago 1993 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5516803 1 Mar 1995 14 May 1996 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5691374 18 May 1995 25 Nov 1997 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5789413 21 Ene 1997 4 Ago 1998 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5834479 6 Nov 1996 10 Nov 1998 Mayer; David J. Method and composition for alleviating pain
US5859257 14 Ago 1996 12 Ene 1999 G. D. Searle & Co. Isoxazole compounds as cyclooxygenase inhibitors
US5861419 11 Jul 1997 19 Ene 1999 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5869498 7 Jul 1997 9 Feb 1999 Virginia Commonwealth University Pain alleviating drug composition and method for alleviating pain
AU734275B2 Título no disponible
CA2023349A1 15 Ago 1990 18 Feb 1991 Manfred Lohner Agents for the treatment of conditions of heavy pain and processes for preparing said agents
CA2081604A1 28 Oct 1992 1 May 1993 Robert B. Raffa Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
EP0068838B1 25 Jun 1982 17 Sep 1986 The Upjohn Company Analgesic process and composition
EP0388125A1 12 Mar 1990 19 Sep 1990 Beecham Group Plc Medicament
EP0654263A1 17 Nov 1994 24 May 1995 Euro-Celtique S.A. Sustained release composition and a method of preparing pharmaceutical compositions
EP0654263B1 17 Nov 1994 23 Ene 2002 Euro-Celtique S.A. Method for preparing a sustained release composition
WO1997017978A1 13 Nov 1996 22 May 1997 Pitmy International N.V. Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
WO1997025988A1 17 Ene 1997 24 Jul 1997 Eli Lilly And Company Methods of treating or preventing pain or nociception
WO1997032857A1 1 Mar 1997 12 Sep 1997 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
WO1999007413A1 26 May 1998 18 Feb 1999 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
1 "Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats;" D. Dirig et al., J. Pharmacol. and Experimental Therapeutics vol. 285, No. 3, pp. 1031-1038 (1998).
2 Abstract of: Dvornik D.M., "Tissue selective inhibition of prostaglandin biosynthesis by etodolac," Journal of Rheumatology, Supplement 47:40-7, Feb. 1997.
3 Abstract of: Emery P., "Clinical implications of selective cycloxygenase-2 inhibiton," Scandinavian Journal of Rheumatology-Supplement 102:23-8, 1996.
4 Abstract of: Flower R.J., "New directions in cyclooxgenase research and their implications for NSAID-gastropathy," Italian Journal of Gastroenteroly, 28 Suppl. 4:23-7, Dec. 1996.
5 Abstract of: Hosie J. et al., "Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium," British Journal of Rheumatology, 35 Suppl. 1:39-43, Apr. 1996.
6 Abstract of: Isakson P. et al., "Discovery of a better aspirin," Advances in Prostaglandin, Thromboxane, & Leukotriene Research 23:49-54, 1995.
7 Abstract of: Jouzeau J.Y. et al., "Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drus," Drugs 53(4):563-82, Apr. 1997.
8 Abstract of: Kurumbail R.G. et al., "Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents," Nature, 384(6610):644-8, Dec. 19-26, 1996.
9 Abstract of: Masferrer J.L. et al, "Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract," Gastroenterology Clinics of North America 25(2):363-72, Jun. 1996.
10 Abstract of: Ogino K. et al., "Evaluation of pharmacological profile of meloxicam as an anti-inflammatroy agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1," Pharmacology 55(1):44-53, Jul. 1997.
11 Abstract of: Pairet M. et al., "Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications," Fundamental & Clinical Pharmacology 10(1):1-17, 1996.
12 Abstract of: Santos et al., "Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in Mice," Inflammation Research (1998), 47(7) pp. 302-307, Chem. Abst. vol. 129 (Columbus, OH).
13 Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996).
14 Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1998).
15 Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In Evaluation and Treatment of Chronic Pain, 2nd ed., William & Wilkins pp. 363-383. (1992).
16 Beaver, WT. Combination Analgesics. American Journal of Medicine, 77 (Suppl 3A), pp. 38-53. (1984).
17 Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. Neuropharmacology vol. 33, pp. 1609-1611. (1994).
18 Brasseur. L. Revue des therapeutiques pharmacolgoiques actuelles de la douleur. Drugs,53 Suppl 2, pp. 10-17. (1997).
19 Capasso, Anna et al. "Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum" European Journal of Pharmacology vol. 330, pp. 199-204, 1997.
20 Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cartiona Hay and Jacqueline de Belleroche, NeuroReport 8, 1249-1251, (1997).
21 Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. and Applied Skin Phys. 11: 273-278, (1998).
22 Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G. K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp. 3-6, (1987).
23 Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, vol. 16, No. 2, pp. 181-206, (1996).
24 Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).
25 Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. vol. 12 pp. 1063-1073 (1998).
26 Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. Eur. J. Pharmacology 387 (1) R1-R3 (2000).
27 Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998).
28 Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointesinal Toxicity. Gut, 39, Suppl. 3, A151. (1996). Abstract.
29 Degner, Frank, et al., "Efficacy and Tolerability of Meloxicam in an Observational, Controlled Cohort Study in Patients with Rheumatic Disease", Clin Therapeutics (Nov. 2000) 22: 400-410.
30 Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47: 79-85, (1998).
31 Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. Europeam J. Pharm 355 pp. 211-217, (1998).
32 Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) By NSAIDS: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., Inflammopharmacology 4; 61-70, (1996).
33 Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," Brit. J. Rheumatology 1996:35 (suppl. 1):68-77.
34 Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15 , (1996).
35 Donelly et al. COX-II Inhibitors-a new generation of safer NSAIDS? Alimentary Pharmacology and Therapeutics, 11, 2, pp. 227-236. (1997).
36 Donelly et al. COX-II Inhibitors—a new generation of safer NSAIDS? Alimentary Pharmacology and Therapeutics, 11, 2, pp. 227-236. (1997).
37 Dray et al. New Pharmacological Strategies for Pain Relief. Annual Review of Pharmacology &Toxicology, 36, pp. 253-280. (1996).
38 Effect pf meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. British Journal of Anaesthesia 84 (2) 151-4 (2000).
39 Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflamatory Agent with Favorable Gastrointestinal Tolerance," Inflamm. Res. 44:423-433 (1995).
40 Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," Brit. J. Rheumatology 1996:35 (suppl. 1): 4-12.
41 Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. British Journal of Rheumatology. 34, Abstract Suppl. 1, p. 48. (1995). Abstract.
42 Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones, Vaughn et al. British Journal of Pharmacology 123 (8) 1479-81 (1998).
43 Etches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. Anesthesia & Analgesia, 81 (6), pp. 1175-1180. (1995).
44 Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis," The American Journal of Medicine, vol. 95 (Sup. 2A), pp. 10S-18S (1993).
45 Friedel et al., "Nabumetone-A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," Drugs vol. 45 (1), pp. 131-156 (1993).
46 Friedel et al., "Nabumetone—A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," Drugs vol. 45 (1), pp. 131-156 (1993).
47 Frölich, J.C., "A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes," TiPS, Jan. 1997, vol. 18, pp. 30-34.
48 Furst, D.E., "Meloxicam: selective COX-2 inhibition in clinical practice," Semin Arthritis Rheum, vol. 26, No. 6, Suppl. 1, pp. 21-27, 1997.
49 Goodman & Gillman's (1996), The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-HIll, New York pp. 535 and 551-552 (1995).
50 Goodman & Gillman's (1996), The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-HIll, New York pp. 654-655.
51 Goodman and Gillman's The Pharmacological Basis of Therapeutics, 6th edition, Macmillan Publishing Co., "Chapter 22: Opioid Analgesics and Antagonists," p. 494-497, esp. Tables 22-1, p. 496 (1980).
52 Goodman and Gilman's: The Pharmaceutical Basis of Therapeutics, "Chapter 22: Opioid Analgesics and Antagonists," MacMillan Publishing Co., Inc., pp. 494-497, esp. Table 22-1, p. 496 (1980).
53 Griswold, D.E., et al., "Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date," Medicinal Research Reviews, vol. 16, No. 2, (1996), pp. 181-206.
54 Hanses et al., "Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration," Arzneim.-Forsch./Drug Res., 46(I), Nr. 1, 57-63 (1996).
55 Hodsman et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. Anaesthesia, 42(9), pp. 1005-1008. (1987).
56 Insel. Chapter 27: Analgesic-Antipyretic and Anti-inflammatory Agents. In Hardman, ed., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition. McGraw-Hill, New York, pp. 654-655. (1996).
57 Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. C.S. Wong et al., British Journal of Anaesthesia 85 (5) 747-51 (2000).
58 Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Viscernonociception Induced by Phenylquinone, Hidenobu Kusuhara, et al. Prostaglandins 55: 43-49, (1998).
59 Kaasalainer et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. Pain, 70, 2-3, pp. 175-183. (1997).
60 Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. Journal of Rheumatology. vol. 24, Suppl 49, pp. 20-24. (1997).
61 Lanes, Stephan et al., "Baseline Risk of Gastrointestinal Disorders Among New Users of Meloxicam, Ibuprofen, Diclofenac, Naaproxen and Indomethacin", Pharmacoepidemiology and Drug Safety (2000) 9:113-117.
62 Lichtblau, L. et al., "Pharmacologic management of cancer pain in rural Minnesota," J Pain Symptom Manage, vol. 12, No. 5, p. 283-9, 1996.
63 Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," Inflammopharmacology (1995) vol. 3(4) pp. 351-361.
64 Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. Journal of Rheumatology, 24 Suppl 49, pp. 9-14. (1997).
65 Mehlisch et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. Journal of Clinical Pharmacology, 37, 9, 863. (1997). Abstract.
66 Merck Index, Twelfth Edition, Merck & Co. Publishers, p. 1194, (1996).
67 NDA 020938 Approval letter and label Apr. 13, 2000; obtained from http://www.accessdata.fda.gov on Oct. 16, 2008.
68 NDA 20-938 Administrative Documents, 1998; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
69 NDA 20-938 Chemistry Review(s), 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
70 NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
71 NDA 20-938 Correspondence, 1998-1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
72 NDA 20-938 Medical Review, completed Aug. 31, 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
73 NDA 20-938 Microbiology Review(s) 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
74 NDA 20-938 Pharmacology Review(s), completed Sep. 17, 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
75 NDA 20-938 Statistical Review(s) 1999; obtained from http:/www.accessdata.fda.gov on Oct. 16, 2008.
76 Office Action issued in connection with Application No. 10/057,632 on Aug. 10, 2006.
77 Office Action issued in connection with Application No. 10/057,632 on Aug. 21, 2007.
78 Office Action issued in connection with Application No. 10/057,632 on Jan. 19, 2005.
79 Office Action issued in connection with Application No. 10/057,632 on Jan. 25, 2007.
80 Office Action issued in connection with Application No. 10/057,632 on Jun. 14, 2005.
81 Office Action issued in connection with Application No. 10/057,632 on Nov. 24, 2009.
82 Office Action issued in connection with U.S. Appl. No. 09/154,354 on Apr. 20, 2000.
83 Office Action issued in connection with U.S. Appl. No. 09/154,354 on Dec. 19, 2000.
84 Office Action issued in connection with U.S. Appl. No. 09/154,354 on Dec. 22, 1999.
85 Office Action issued in connection with U.S. Appl. No. 09/154,354 on Jul. 19, 2001.
86 Office Action issued in connection with U.S. Appl. No. 10//057,630 on Sep. 7, 2004.
87 Office Action issued in connection with U.S. Appl. No. 10/033,055 on Jan. 19, 2005.
88 Office Action issued in connection with U.S. Appl. No. 10/033,055 on Jul. 2, 2004.
89 Office Action issued in connection with U.S. Appl. No. 10/033,055 on Jul. 28, 2006.
90 Office Action issued in connection with U.S. Appl. No. 10/033,055 on Jun. 14, 2005.
91 Office Action issued in connection with U.S. Appl. No. 10/033,055 on May 14, 2004.
92 Office Action issued in connection with U.S. Appl. No. 10/033,055 on Nov. 28, 2006.
93 Office Action issued in connection with U.S. Appl. No. 10/033,055 on Oct. 6, 2005.
94 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Aug. 21, 2007.
95 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Aug. 26, 2004.
96 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Feb. 25, 2008.
97 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Jan. 19, 2005.
98 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Jul. 13, 2009.
99 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Jun. 1, 2006.
100 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Jun. 14, 2006.
101 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Jun. 3, 2008.
102 Office Action issued in connection with U.S. Appl. No. 10/056,347 on May 14, 2004.
103 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Nov. 30, 2006.
104 Office Action issued in connection with U.S. Appl. No. 10/056,347 on Oct. 6, 2005.
105 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Aug. 1, 2006.
106 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Aug. 26, 2004.
107 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Jan. 19, 2005.
108 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Jul. 6, 2004.
109 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Jun. 14, 2005.
110 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Jun. 22, 2009.
111 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Jun. 4, 2008.
112 Office Action issued in connection with U.S. Appl. No. 10/056,348 on May 14, 2004.
113 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Nov. 28, 2006.
114 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Oct. 14, 2008.
115 Office Action issued in connection with U.S. Appl. No. 10/056,348 on Oct. 6, 2005.
116 Office Action issued in connection with U.S. Appl. No. 10/056,475 on May 14, 2004.
117 Office Action issued in connection with U.S. Appl. No. 10/056,475 on Sep. 7, 2004.
118 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Dec. 19, 2006.
119 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Feb. 4, 2009.
120 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Jan. 19, 2005.
121 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Jul. 10, 2007.
122 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Jun. 14, 2005.
123 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Jun. 19, 2006.
124 Office Action issued in connection with U.S. Appl. No. 10/057,630 on May 14, 2004.
125 Office Action issued in connection with U.S. Appl. No. 10/057,630 on May 22, 2008.
126 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Sep. 21, 2007.
127 Office Action issued in connection with U.S. Appl. No. 10/057,630 on Sep. 29, 2005.
128 Office Action issued in connection with U.S. Appl. No. 10/057,632 on Jul. 2, 2004.
129 Office Action issued in connection with U.S. Appl. No. 10/057,632 on May 14, 2004.
130 Office Action issued in connection with U.S. Appl. No. 10/057,632 on May 29, 2008.
131 Office Action issued in connection with U.S. Appl. No. 10/057,632 on Oct. 6, 2005.
132 Office Action issued in connection with U.S. Appl. No. 11/825,938 on Aug. 9, 2007.
133 Office Action issued in connection with U.S. Appl. No. 11/825,938 on Feb. 19, 2010.
134 Office Action issued on Apr. 20, 2000 in connection with U.S. Appl. No. 09/154,354.
135 Office Action issued on Aug. 1, 2006 in connection with U.S. Appl. No. 10/056,348.
136 Office Action issued on Aug. 10, 2006 in connection with U.S. Appl. No. 10/057,632.
137 Office Action issued on Aug. 21, 2007 in connection with U.S. Appl. No. 10/056,347.
138 Office Action issued on Aug. 21, 2007 in connection with U.S. Appl. No. 10/057,632.
139 Office Action issued on Aug. 22, 2007 in connection with U.S. Appl. No. 10/056,348.
140 Office Action issued on Aug. 25, 2010 in connection with U.S. Appl. No. 10/056,347.
141 Office Action issued on Aug. 26, 2004 in connection with U.S. Appl. No. 10/056,347.
142 Office Action issued on Aug. 26, 2004 in connection with U.S. Appl. No. 10/057,631.
143 Office Action issued on Aug. 26, 2010 in connection with U.S. Appl. No. 10/056,348.
144 Office Action issued on Dec. 22, 1999 in connection with U.S. Appl. No. 09/154,354.
145 Office Action issued on Feb. 19, 2010 in connection with U.S. Appl. No. 11/825,938.
146 Office Action issued on Feb. 4, 2009 in connection with U.S. Appl. No. 10/057,630.
147 Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/033,055.
148 Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/056,347.
149 Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/056,348.
150 Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/057,630.
151 Office Action issued on Jan. 19, 2005 in connection with U.S. Appl. No. 10/057,632.
152 Office Action issued on Jan. 7, 2011 in connection with U.S. Appl. No. 10/057,630.
153 Office Action issued on Jul. 13, 2009 in connection with U.S. Appl. No. 10/056,347.
154 Office Action issued on Jul. 2, 2004 in connection with U.S. Appl. No. 10/033,055.
155 Office Action issued on Jul. 2, 2004 in connection with U.S. Appl. No. 10/057,632.
156 Office Action issued on Jul. 28, 2006 in connection with U.S. Appl. No. 10/033,055.
157 Office Action issued on Jul. 6, 2004 in connection with U.S. Appl. No. 10/056,348.
158 Office Action issued on Jun. 17, 2010 in connection with U.S. Appl. No. 11/825,938.
159 Office Action issued on Jun. 19, 2006 in connection with U.S. Appl. No. 10/057,630.
160 Office Action issued on Jun. 22, 2009 in connection with U.S. Appl. No. 10/056,348.
161 Office Action issued on Jun. 3, 2008 in connection with U.S. Appl. No. 10/056,347.
162 Office Action issued on May 14, 2004 in connection with U.S. Appl. No. 10/056,347.
163 Office Action issued on Nov. 15, 2010 in connection with U.S. Appl. No. 11/825,938.
164 Office Action issued on Nov. 24, 2009 in connection with U.S. Appl. No. 10/057,632.
165 Office Action issued on Nov. 30, 2006 in connection with U.S. Appl. No. 10/056,347.
166 Office Action issued on Oct. 14, 2008 in connection with U.S. Appl. No. 10/056,348.
167 Office Action issued on Oct. 26, 2010 in connection with U.S. Appl. No. 10/057,632.
168 Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/033,055.
169 Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/056,347.
170 Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/056,348.
171 Office Action issued on Oct. 6, 2005 in connection with U.S. Appl. No. 10/057,632.
172 Office Action issued on Sep. 21, 2007 in connection with U.S. Appl. No. 10/057,630.
173 Office Action issued on Sep. 29, 2005 in connection with U.S. Appl. No. 10/057,630.
174 Office Action issued on Sep. 7, 2004 in connection with U.S. Appl. No. 10/056,475.
175 Office Action issued on Sep. 7, 2004 in connection with U.S. Appl. No. 10/057,630.
176 Penning et al. Synthesis and Biological Evaluation of the 1, 5-diarylpyrazole class of cylooxygenase-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). Journal of Medicinal Chemistry, 40(9), 1347-65. (1997).
177 Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. Arzneim.-Forsch./Drug Res. 46 (I), 57-63 (1996).
178 Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With an Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996).
179 Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With an Improved Safety Profile Through Preferential Inhibition of COX-2,G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996).
180 Pharmacovigilance Aug. 1994.
181 Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain, 73, 3 pp. 401-406. (1997).
182 Polisson. Non-steroidal Anti-inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. The American Journal of Medicine, 100 (Suppl 2A), pp. 2A-31S-2A-36S. (1996).
183 Prescribing Points, vol. 8.4, Jun. 1999.
184 Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; Jul. 28, 2003.
185 Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflamatory Drug," Drugs of Today vol. 32, No. 5 (1996), p. 9. 365-384.
186 Rang et al. New molecules in analgesia. British Journal of Anesthesia, 75, pp. 145-156 (1995).
187 Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," Drug Safety vol. 15(4), pp. 249-260 (Oct. 1996).
188 Richy, F., et al., "Time dependent risk of gastrointestinal complications induced by non-steroid anti-inflammatory drug use: a consensus statement using a meta-analytic approach", Ann Rhuem Dis (2004) 64:759-766.
189 Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. J Rheumatoloty, 24, Suppl. 47, pp. 32-39. (1997).
190 Rorarius et al. , "Non-steroidal Anti-inflamatory Drugs for Postoperative Pain Relief," Current Opinion in Anesthesiology , 7:358-362 (1994).
191 Rorarius et al., "Non-Steroidal Anti-Inflammatory Drugs for PostOperative Pain Relief," Curr. Opin. In Anaesthesiology, 7, 358-362, (1994).
192 Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cycloocygenase 2 in Inflamation and Pain," PNAS USA vol. 91 (Dec. 1994) pp. 12013-12-17.
193 Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX ‘Selectivity’. Journal of Clinical Rheumatology, 2 (3), pp. 135-140. (1996).
194 Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. Journal of Clinical Rheumatology, 2 (3), pp. 135-140. (1996).
195 Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); Dec. 1, 1998; obtained from http://www.citizen.org/publications/print-release.cfm?ID=6653 on Oct. 28, 2008.
196 Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); Dec. 1, 1998; obtained from http://www.citizen.org/publications/print—release.cfm?ID=6653 on Oct. 28, 2008.
197 STN: File Registry printout of Registry No. 162054-19-5 (Jun. 14, 2004 ).
198 Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. Journal of Clinical Pharmacolology, 37 (10), pp. 908-915. (1997).
199 Swingle et al., "Preclinical Pharmacological Studies with Nimesulide," Drugs Exptl. Clin. Res. vol. X (8-9); pp. 587-597 (1984).
200 Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats, J.M. Lashbrook, et al. Pain 82 (1) 65-72 (1999).
201 Tanaka et al., "Pharmacological Studies of the New Antiinflamatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," Arzneihm-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992).
202 Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Muscoskeletal Disease: A Canadian Consensus. Canadian Medical Association Journal, 155, 1, pp. 77-88. (1996).
203 The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996).
204 The Merck Index Results, "Nimesulide," downloaded from http://themerckindex.cambridgesoft.com/TheMerckIndex/default.asp?; downloaded on Aug. 10, 2007.
205 The Merck Index, 12th edition, Merck & Co. Publishers, p. 1194 (1996).
206 The Pharmacological Basis of Therapeutics, 8th edition, p. 665 (1990).
207 Therapeutics Initiative, Feb. 1995.
208 Therapeutics Initiative, Jan. 1997.
209 Therapeutics Initiative,Jan./Feb. 2001.
210 Translation of Office Action dated Nov. 1, 2001, issued in connection with Russian Federation Patent Application No. 2000109552.
211 Van Hecken, Anne, et al., "Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers", J Clin Pharmacol (2000) 40: 1109-1120.
212 Van Ryn et al. Selective cycloocygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. Expert Opinion on Investigational Drugs. pp. 609-614. (1997).
213 Vane et al. New insights into the mode of action of anti-inflammatory drugs. Inflammation Research. 44, (No. 1), pp. 1-10 (1995).
214 Vane, J. Towards a better aspirin. Nature, 367, pp. 215-216. (1994).
215 Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. Gastroenterology, 112, 3, pp. 1000-1016. (1997).
216 Wojtulewski et al., "a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," Brit. J. Rheumatology 1996:35 (suppl. 1):22-28.
217 Wollheim, F.A., "Current pharmacological treatment of osteoarthritis," Drugs, vol. 52, Suppl. 3, p. 27-38, 1996.
Clasificación de EE.UU. 514/282, 514/406
Clasificación internacional A61P25/00, A61F2/02, A61K31/485, A61K45/00, A61K9/08, A61K9/10, A61P25/04, A61K31/12, A61K45/06, A61K9/48, A61K9/20, A61P29/00, A61K31/415, A61K31/54, A61K9/28, A61K31/4353, A61K9/02
Clasificación cooperativa A61K31/54, A61K31/415, A61K31/485, A61K31/137, A61K45/06, A61K31/135, A61K31/4353